Saturday, February 18, 2012

Men opting for costly new prostate cancer treatment

NEW YORK (Reuters Health) -

Men diagnosed with localized prostate cancer are more likely to be treated with proton beam therapy, a novel form of radiation therapy, if the technology is available nearby, a new study found.

In the study, researchers examined the treatment choices of nearly 20,000 men living inside or outside of a regional market for Loma Linda University, a hospital in Southern California with a proton beam facility. All men were diagnosed with low- to intermediate-risk prostate cancer.

The treatment is often billed as having lower impotence and incontinence rates than other radiation treatment options, but there's a lack of evidence to support this.

Despite the added costs, there's no evidence to suggest that proton beam therapy results in better outcomes than other forms of prostate cancer treatment, including other forms of radiation, surgery or hormone therapy.

With the healthcare crisis looming and multiple treatment options available, newer, more expensive procedures for prostate cancer should be validated before they are implemented.

Read the full Reuters Health report:
Men opting for costly new prostate cancer treatment


Thursday, February 16, 2012

In prostate cancer, other death risks may be higher

NEW YORK (Reuters Health) -

Some men with prostate cancer may have increased risks of dying from causes other than the cancer itself, a new study finds.

Researchers found that when men had their prostate cancer diagnosed after developing symptoms -- and not after screening tests -- they had heightened risks of dying from heart problems or other cancers.

It's not clear what to make of the findings at this point. Mainly, they raise questions for future studies, said Dr. Anthony D'Amico, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston.


Read the full Reuters report:
In prostate cancer, other death risks may be higher


DiagnoCure gets FDA nod for prostate cancer test, shares jump

(Reuters) -

Canada's DiagnoCure Inc said it received U.S. regulatory approval for a prostate cancer test that may help avoid unnecessary biopsies, sending its shares to their highest in about 18 months.

The urine-based test -- named Progensa PCA3 -- will be used with other patient information to help decide on repeat biopsy in men of 50 years or older.

The company said the PCA3 test will now be available for sale in the United States, Canada and the European Union.

Read the full Reuters report:
DiagnoCure gets FDA nod for prostate cancer test, shares jump


Saturday, February 11, 2012

Prostate Size May Be Clue to Severity of Cancer


FRIDAY, Feb. 10 (HealthDay News) --

The size of a man's prostate gland may help doctors predict the severity of his prostate cancer, according to a new study.

Researchers from the Vanderbilt-Ingram Cancer Center in Nashville, Tenn., found smaller prostates that produce higher levels of prostate specific antigen (PSA) in the blood are more often linked to serious forms of prostate cancer that require aggressive treatment.

What it's really about is the ratio of PSA to size, or PSA density, meaning that a small prostate that is making a lot of PSA is likely to be due to a bad tumor, whereas a large prostate making a lot of PSA is likely to be due to benign enlargement of the prostate (BPH).

The study's authors suggest the findings could help doctors determine the best course of treatment for patients with prostate cancer. For instance, low-risk patients with a small prostate might benefit from aggressive treatment.

The researchers pointed out that the findings are significant since men with prostate cancer who are considered low-risk may receive less aggressive treatment or just be placed under observation.

The researchers cautioned that more accurate tests are still needed to determine which cancers are actually threatening to patients.


Read the full HealthDay News report:
Prostate Size May Be Clue to Severity of Cancer

Erectile drugs might help premature ejaculation

NEW YORK (Reuters Health) -

Most studies looking at whether erectile dysfunction drugs can help men overcome premature ejaculation problems agree that the pills make a difference, but much of the research is flawed, according to a new review of the evidence.

The drugs, which go by the brand names Viagra, Levitra and Cialis, are intended to treat men who have problems getting and keeping an erection.

Asimakopoulos and his colleagues ran into problems trying to compare the studies. For one, they didn't always agree on the definition of premature ejaculation.

The other stumbling block to the group's analysis was that fewer than half of the studies compared the drugs to a placebo, a standard for high-quality studies that helps researchers determine whether the drug itself is responsible for any effects seen.

"There seems to be a global positive effect of these drugs in delaying ejaculation; however, the existing evidence is still partial and their role remains controversial,"


Read the full Reuters Health report:
Erectile drugs might help premature ejaculation


Friday, February 10, 2012

Heart Disease May Be Risk Factor for Prostate Cancer (HealthDay)


THURSDAY, Feb. 9 (HealthDay News) -- Heart disease may be a risk factor for prostate cancer, a new study suggests.

If this link is confirmed in future research, it means that lifestyle changes that reduce heart disease risk -- such as weight loss, exercise and a healthy diet -- may also protect men against prostate cancer, the Duke Cancer Institute researchers said.

The Duke researchers found that men with coronary artery disease had a 35 percent greater risk of developing prostate cancer over time and a 24 percent greater risk of being diagnosed with prostate cancer within the first two years of the study compared to men who did not have heart disease.

Read the full HealthDay News report:
Heart Disease May Be Risk Factor for Prostate Cancer

Friday, February 3, 2012

Science Shows How Exercise Might Help in Prostate Cancer (HealthDay)

TUESDAY, Jan. 31 (HealthDay News) --

Vigorous exercise causes changes in some 180 prostate genes among men with early stage prostate cancer, a new study suggests.

Included are genes known to suppress tumor growth and repair DNA, which might mean that exercise could prevent or delay progression of the disease, the researchers said.

June Chan, associate professor of epidemiology and biostatistics, and urology at the University of California, San Francisco said that there are limitations to this study. Most important, the study was small and so the results could be by chance, she said.

"If confirmed, the results suggest that vigorous physical activity might offer protection against prostate cancer progression," Chan said.


Read the full HealthDay News report:
Science Shows How Exercise Might Help in Prostate Cancer